NZ's Fisher and Paykel rises; Morgan Stanley sees tariffs as key focus ahead of annual results

Fisher & Paykel Healthcare

27/05/2025 01:37

** Shares of New Zealand's Fisher & Paykel Healthcare Corp FPH.NZ up 1% at NZ$36.53

** The medical equipment maker to report FY25 results on Wednesday

** Morgan Stanley expects FY26 NPAT forecast of NZ$422 million ($253.16 million) vs Visible Alpha estimate of NZ$426 million

** Brokerage says FY26 forecasts imply limited gross margin expansion due to expected U.S. tariff impacts on products manufactured in New Zealand

** MS to focus on impacts from most recent U.S. flu season and trends for new applications growth in co's hospitals segment

** Brokerage also looking for co's updates on newer mask launches and commentary on potential impact of GLP-1s on the obstructive sleep apnea (OSA) market

** Stock rated "equal-weight" with a price target of NZ$36.7

** Fisher & Paykel down 5.1% YTD, including current session's moves

($1 = 1.6669 New Zealand dollars)

 (Reporting by Nikita Maria Jino in Bengaluru)

 ((Nikita.Jino@thomsonreuters.com;))